Connect with us

Hi, what are you looking for?


Moderna stock remains a great pick for long-term investors: Analyst

Moderna Inc (NASDAQ: MRNA) has taken a big hit over the past seven weeks, which, as per an Oppenheimer analyst, is a fantastic opportunity for the long-term investors.

Reasons to own the Moderna stock

At a price-to-earnings multiple of just over four, the biotech firm is quite attractive in terms of valuation. But Hartaj Singh is bullish on the “fundamental” story here as well.

This morning on CNBC’s “Squawk on the Street”, he recommended that investors buy Moderna stock despite the near-term challenges.

They’re literally the leader in mRNA therapeutics. Moderna will most likely solve very complex diseases with its mRNA therapeutics going forward. They’re in the lead in manufacturing, pre-clinical and clinical development.

Singh is bullish on Moderna even after New York terminated the vaccine mandate for private sector and student athletes on Tuesday.

Moderna is a five-to-ten-year story

In its latest reported quarter, the Massachusetts-headquartered company took a $500 million hit on expiring COVID shots. The Oppenheimer analyst agrees such challenges will continue in the near-term (six to eighteen months) but said:

If you’re a believer of mRNA therapeutics being a fairly large segment ($100 billion to $150 billion) of therapeutics sales five or ten years from now, you should keep owning Moderna and maybe even buy some on extreme dips.

Singh has confidence in the management team at Moderna as well. Despite the post-COVID struggles, the Nasdaq-listed firm reported better-than-expected profit and revenue for its Q2 in August.

Wall Street has a consensus “overweight” rating on the Moderna stock as well.

The post Moderna stock remains a great pick for long-term investors: Analyst appeared first on Invezz.

Enter Your Information Below To Receive Free Trading Ideas, Latest News And Articles.

    Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

    You May Also Like


    Inflation appears to be on the decline. The Personal Consumption Expenditures Price Index (PCEPI), which is the Federal Reserve’s preferred measure of inflation, grew...


    Solana (SOL/USD) is enormously underrated as a cryptocurrency project, even with its hiccups – including the latest exploit on one of the ecosystem apps....

    Editor's Pick

    The new eSIM infrastructure will help modernise the IoT connectivity market with fast, secure connections and reduced vendor lock-in. 1oT, a tech startup from...


    The latest Job Openings and Labor Turnover Survey from the Bureau of Labor Statistics shows the total number of job openings in the economy...

    Disclaimer:, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2023